Cellosaurus cell line KTOR2-RE (CVCL

Entry history
Cell line name	KTOR2-RE
Accession	CVCL_E6D9
Resource Identification Initiative	To cite this cell line use: KTOR2-RE (RRID:CVCL_E6D9)
Comments	Population: Japanese. Donor information: Established from the patient after relapse and acquired resistance to ALK inhibitors (PubMed=31900393). Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations	Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK; Note=E13A20 v1 fusion (PubMed=31900393). Mutation; HGNC; HGNC:427; ALK; Simple; p.Leu1196Met (c.3586C>A); ClinVar=VCV000376135; Zygosity=Unspecified (PubMed=31900393).
Disease	Lung non-small cell carcinoma (NCIt: C2926)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual	CVCL_E6D8 ! KTOR2
Sex of cell	Male
Age at sampling	76Y
Category	Cancer cell line
Publications	PubMed=31900393; DOI=10.1038/s41467-019-13771-5; PMCID=PMC6941996 Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo ...Show all 17 authors... , Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai; Show fewer authors YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat. Commun. 11:74.1-74.16(2020)
Entry creation	10-Apr-2025
Last entry update	10-Apr-2025
Version number	1